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IntroductIon
Macrophage activation syndrome (MAS) is a life 
threatening complication of chronic rheumatic dis-
eases in childhood1-2. Although it is seen most com-
monly in systemic juvenile idiopathic arthritis, it has 
also been described in association with systemic lupus 
erythematosus, juvenile dermatomyositis and Kawa-
saki disease3-5. It is characterized by an uncontrolled 
activation of T lymphocytes and macrophages, which 
leads to a systemic inflammatory response inducing 
multiorgan infiltration and dysfunction5. MAS can 
present as fever of unknown origin, cytopenias, organ 
failure (respiratory, cardiovascular, hepatic, renal) or 
encephalitis1,3. Diagnosis of MAS can be difficult, be-
cause there are no pathognomonic clinical or labora-
tory findings and it is based on decreed diagnostic cri-
teria: two clinical, fever and splenomegaly and three 
of the five laboratory ones, cytopenia, hyper-triglycer-
idemia and/or hypofibrinogenemia, hyperferritinemia, 
hemophagocytosis in bone marrow, absent or low NK 
cell activity and increased CD25 levels2-5. Infections, 
particularly viral, have been suggested to play a trig-
gering role6. We describe a case of systemic vasculitis 
complicated with MAS triggered by Parvovirus B19 
infection a long time after the disease onset.
case report
A 7 year old female patient, diagnosed with an un-
classified vasculitic syndrome 6 years previously, was 
admitted with a week’s history of non remitting fever 
of up to 39,5oC, diffuse maculopapular rash, paleness, 
fatigue and malaise. Her main disease started at the 
age of 9 months when a systemic ANCA positive vas-
culitis of unclassified type was diagnosed7. 
The disease was refractory to conventional thera-
peutic regiments. Persistent fever, rash and/or peri-
carditis recurred three or more times per year. During 
the 6-year period of the disease course she had taken 
steroids (peros or pulses), cyclosporine, intravenous 
immunoglobulin (IVIG), methotrexate, azathioprine, 
cyclophosphamide and anti-TNF (etanercept) without 
succeeding long-term remission. Lastly, she was put 
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on anakinra, a recombinant IL-1 receptor antagonist 
and she responded dramatically getting into remission 
for about a year. 
On admission’s clinical examination the patient 
was in no acute distress. Her temperature was 38oC, 
heart rate 90 beats per minute and blood pressure 
100/60 mmHg. Moreover, hepatomegaly (3 cm), sple-
nomegaly (4 cm) and mild generalized lymphadenop-
athy (1-1.5cm) were ascertained. Laboratory evalua-
tion revealed a leucocytosis with neutrophilia (11.5 x 
109/L with 83% neutrophils), with normal hematocrit 
(36%) and platelet count (409 x 109/L). Acute face re-
actants were moderately elevated (ESR: 53 mm/hr and 
CRP: 9.29 mg/dl) as well as liver enzymes (AST: 115 
U/l, ALT: 57 U/l, LDH:2374 U/l) while renal func-
tion (urea, creatinine and urine analysis) was normal. 
Her chest radiograph showed dense bilateral alveolar 
infiltrates, abdominopelvic ultrasonography revealed 
mild enlargement of the abdomen lymph nodes and 
heart ultrasonography was consistent with mild peri-
carditis. Bone marrow aspiration was normal but her 
serum immunologic profile showed a raised count of 
activated B cells (CD23: 28%, normal: 0-1.5) and low 
CD4/CD8 ratio (0.6, normal: 1-2.5). 
According to these clinical and laboratory data, in-
fection and/or flare of the disease was considered and 
broad-spectrum antibiotics (ceftazidime plus amika-
cin) were introduced after the collection of blood and 
urine cultures and serologic investigation for bacterial 
or viral infection. Furthermore, anakinra was inter-
rupted and intravenous cyclophosphamide as well as 
IVIG was initiated. After this treatment fever and rash 
were slightly reduced but fatigue and malaise sus-
tained. Ten days later the patient had a deterioration 
of her general condition with persistent high-grade 
fever (>40o C) resistant to anti-febrile drugs (parac-
etamol, mefenamic acid and ibuprofen) accompanied 
by hepatosplenomegaly, irritability and altered mental 
status. Laboratory work-up revealed neutropenia (1.2 
x 109/L, normal: 1.5-8), anemia (8.2 g/dl), thrombo-
cytopenia (45 x 109/L, normal: 150-400), hyperfer-
ritinemia (13000 ng/ml, normal: 10-140), high levels 
of LDH (4964 U/l), hypertriglyceridemia (600 mg/dl, 
normal: 0-150) and sudden fall of ESR (25 mm/1h) 
and fibrinogen (2.8 g/dl, normal: 3.5-5.2) in parallel 
with coagulation disturbances (D-dimmers 4615 μg/l, 
normal: 50-285, aPTT 50s, normal: 24-36 and PT 17s, 
normal: 10-14). These clinical and laboratory findings 
(fever, splenomegaly, pancytopenia, hypertriglyglyc-
eridemia, hypofibrinogenemia and hyperferritinemia) 
fulfilled the proposed diagnostic criteria for MAS 
syndrome3-5. In addition, serological tests for viral in-
fections revealed a probable Parvo B19 virus infection 
(positive IgM antibodies by ELISA in a title of 0.473, 
normal: cut off 0.3), while CMV, EBV, Coxsakie, 
Echo, HIV, HCV and HBV serology was negative as 
it was all cultures and serologic investigations for bac-
terial infections. Unfortunately, the further Parvovirus 
evaluation with DNA analysis by PCR and IgG anti-
body measurement was unworkable.
Treatment with intravenous pulse methylpredniso-
lone (30mg/Kg/day) for 3 consecutive days in combi-
nation with intravenous cyclosporine (5 mg/Kg/day in 
2 divided doses) was started and fresh frozen plasma, 
platelets, packed red blood cells, and albumin were 
added in order to correct coagulation defects and ane-
mia. But despite this rigorous treatment the patient’s 
condition was rapidly deteriorated. Thirteen days af-
ter admission she developed seizures, confusion and 
unconsciousness and was transferred to the intensive 
care unit. She further lapsed into coma with multiple 
organ failure and died 6 days later despite maximum 
intensive care support. 
dIscussIon
MAS is a rare and potentially fatal condition of rheu-
matic diseases. Unfortunately, diagnosis can be dif-
ficult at onset and confusable8. Our patient initially 
presented with clinical and laboratory features consis-
tent with an infection and/or flare of the underlying 
disease. The presence of a Parvo B19 positive IgM an-
tibodies support the hypothesis of a recent Parvovirus 
infection but it was impossible to confirm the diagno-
sis with DNA analysis by PCR. MAS was suspected 
about a week after admission but the bone marrow as-
piration obtained at that time did not reveal elements 
of hemophagotytosis and a further bone marrow as-
piration was not obtained due to the rapid deteriora-
tion of the patient’s clinical condition. Unfortunately, 
although parvovirus B19 associated MAS carries a 
better prognosis compared with other viruses, in our 
case it was fatal1,6,9,10.
The pathophysiology of MAS involves dysregu-
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lation of T-cytotoxic lymphocytes and natural killer 
cells, which fail to clear infected cells resulting in 
persistent antigen activation of T cells and excessive 
production of cytokines. The cytokine storm leads to 
abnormal production and activation of macrophages 
which display an increased phagocytosis of blood el-
ements3-6. This immunohaematological process of re-
ticuloendothelial system is currently classified among 
the reactional histiocytoses and MAS is also named as 
autoimmune disease associated reactive hemophago-
cytic lymphoistiocytosis (ReHLH)1,5,11.
Diagnosis of MAS/ReHLH can be difficult, espe-
cially in early phases, because there are no pathogno-
monic clinical findings and it must be differentiated 
by infections, sepsis, thrombotic thrombocytopenic 
purpura, disseminated intravascular coagulation or a 
flare up of an underlying disease. Diagnostic criteria 
were proposed in 1991 by a study group of histiocyte 
society and modified in 2004 3-5,11. They suggest that 
MAS diagnosis is established if five of eight diagnos-
tic criteria are fulfilled: two clinical criteria, fever and 
splenomegaly and three laboratory ones, cytopenia, 
hyper-triglyceridemia and/or hypofibrinogenemia 
and evidence of hemophagocytosis in bone marrow, 
spleen or lymph nodes. Recently three new diagnostic 
criteria have been proposed, including hyperferritine-
mia, increased soluble CD25 levels and absent or low 
natural killer cell activity3-5,12.
Our patient fulfilled 5 of the 8 criteria for diagnosis 
of MAS: fever, splenomegaly, cytopenias, hyperfer-
ritinemia and hypertriglyceridemia plus hypofibrino-
genemia. Unfortunately, evaluation of soluble CD25 
levels and natural killer cell activity was unworkable. 
Hemophagocytosis in bone marrow was not found 
probably due to the fact that aspiration was performed 
early in the disease course, so it does not exclude the 
diagnosis of MAS3,13.
Early recognition of MAS and aggressive therapy 
are critical. Clinical differentiation from a typical flare 
of the underlying rheumatic disease is vital, as delay 
in administration of specific therapy may be followed 
by a rapidly fatal course13-14. High dose corticosteroid 
treatment is the suggested initial treatment of choice 
in MAS, which can be effective in almost half of pa-
tients with MAS. Second line agents used include 
cyclosporine, etoposide and IVIg13. Finally, anti-thy-
mocyte globulin, anti-TNF, anti-interleukin-2Ra and 
other monoclonal antibodies (anti-CD20) have been 
used in the setting of rheumatic disease or malignan-
cies associated with MAS3-5, 12,13.
MAS can be fatal with a mortality of 8-22% in dif-
ferent reported series. Various prognostic factors have 
been suggested as delayed diagnosis, severe multior-
gan failure, severe neutropenia and coagulopathy as 
well as the presence of CNS disease and poor response 
to therapy1-5, 9. In our patient, poor response to treat-
ment of the underline disease and CNS involvement 
probably contributed to the fatal outcome of MAS 
despite the early administration of the specific thera-
peutic management with methylprednisolone pulse, 
cyclosporine and IVIg. 
In conclusion, MAS is a rare and potentially le-
thal complication of childhood rheumatic diseases. 
Unfortunately diagnosis can be difficult at onset but 
is critical because prognosis is related to how early 
aggressive treatment is started. A better understanding 
of its pathophysiology can lead to further improve-
ment in the management of MAS. At last, physicians 
should take into account that patients at high risk of 
developing MAS are not only those with Systemic on-
set Juvenile Idiopathic Arthritis, but with every other 
rheumatic diseases of childhood including vasculitic 
syndromes as well.
Abbreviations
MAS = Macrophage activation syndrome, ReHLH = Re-
active hemophagocytic lymphohistiocytosis, ANCA = An-
tinuclear cytoplasmic autoantibodies, IVIG = Intravenous 
immunoglobulin
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ΠΕΡΙΛΗΨΗ: Το σύνδρομο διέγερσης μακροφάγων (MAS) είναι μια δυνητικά θανατηφόρος επιπλοκή των χρόνιων ρευματι-
κών νοσημάτων της παιδικής ηλικίας και συχνότερα της συστηματικής νεανικής ιδιοπαθούς αρθρίτιδας. Οι λοιμώξεις, ιδίως 
οι ιογενείς, πιθανολογείται ότι αποτελούν εκλυτικό παράγοντα στην πρόκληση του συνδρόμου. Περιγράφεται η περίπτωση 
ενός παιδιού με αταξινόμητη συστηματική αγγειΐτια με θετικά ANCA αντισώματα το οποίο ανέπτυξε θανατηφόρο MAS 
πιθανόν λόγω λοίμωξης από παρβοϊό Β19.
Λέξεις Κλειδιά: Σύνδρομο διέγερσης μακροφάγων, Αντιδραστική αιμοφαγοκυτταρική λεμφοϊστιοκύττωση, Λοίμωξη από παρ-
βοϊό Β19, Αταξινόμητη συστηματική αγγειΐτιδα, Ανακίνρα.
Σύνδρομο διέγερσης μακροφάγων σε παιδί με αταξινόμητη συστηματική  
αγγειΐτιδα πιθανόν λόγω λοίμωξης από παρβοϊό Β19.
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